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A B S T R A C T
We report a case of a 71-year-old male with multiple primary malignancies involving kidney and urinary bladder,
combined with synchronous lymphoma. The patient was admitted to the hospital because of painless gross hematuria.
Examination revealed tumor of the right kidney and papillary tumor in the urinary bladder and enlarged lymph nodes
along aorta and inferior vena cava. Transurethral resection of bladder tumor (TUR), radical nephrectomy of the right
kidney and retroperitoneal lymphadenectomy were performed. Pathohistologic evaluation, together with immunohisto-
chemistry, gave the patient the final diagnosis of renal cell carcinoma (RCC), urothelial carcinoma of the urinary blad-
der and B- small cell Non-Hodgkin lymphoma (B-CLL).
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Introduction
Multiple primary malignancies are tumors which de-
velop independently either in the same tissue on differ-
ent localizations or in different tissues. The reason why
it happens is unknown, in some cases it can be related to
therapy or genetics and in others it can be epigenetic.
Epigenetic factors are surely more important in the older
group, with factors influencing carcinogenesis such as
aging, enviromental carcinogens, viral infection, hor-
monal factors, gender and underlying genetic altera-
tions1. The occurence of multiple neoplasms in a single
patient is not a rare phenomenon. The incidence varies
from 1–11% of all neoplasms2. The incidence increases
with age3.
We present this case to add it to the database, docum-
menting the association of three primary synchronous
malignancies – Non Hodgkin lymphoma, renal cell carci-
noma and bladder carcinoma.
Case Presentation
A 71-year old Caucasian man was admitted for recur-
rent episodes of painless hematuria. Abdominal ultra-
sound showed a lesion in the right kidney measuring 51 ´
59 mm and a papillary tumor in the left part of the uri-
nary bladder measuring 27 mm its largest diameter.
Computed tomography scan of the abdomen and pelvis
confirmed the diagnosis and dimensions of the men-
tioned tumors in the rignt kidney and urinary bladder
(Figure 1). However, lymph node packages along the
aorta and vena cava were detected, with largest lymph
nodes up to 1 cm in diameter. Blood and biochemical
tests were normal and without significant changes.
After cystoscopic confirmation of the papillary tumor
mass in the urinary bladder, transuretheral resection un-
der spinal anesthesia was performed in the same act.
Postoperative course was uneventful.
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Three weeks after TUR, nephrectomy was performed
through the 10th intercostal space on the right side in
the lumbal area under general anesthesia. In the same
act, lymphadenectomy of enlarged paracaval, retrocaval,
precaval and interaortocaval lymph nodes from the level
of the right suprarenal gland to the right iliac artery was
performed. Enlarged lymph nodes existed proximal as
well as distal from the spot of surgery.
Gross examination of the resected specimen revealed
a normal sized kidney (L:W:T=12´6´5 cm) with peri-
nephric fat tissue and 7.5 cm long part of ureter. At the
lower pole of the kidney was a circumscribed tumor
mass, 3.5 cm in diameter with solid, soft, yellowish and
partly hemorrhagical cut surface. On histological exami-
nation we found infiltration to the adjacent renal tissue
and to the inner part of renal capsule, but however, there
was no invasion to the adjacent fat tissue. Resection mar-
gins, together with ureter, renal vein and artery, calyceal
and pelvic mucosa, were uninvolved by the tumor. Micro-
scopic morphology revealed solid, tubuloalveolar and
pseudopapillary growth pattern of relatively small tumor
cells with scanty, mostly eosinophylic and only partly
clear cell cytoplasm with large nuclei and conspicious nu-
cleoli, with no significant mitotical activity (up to 2
mitotical figures per 10 HPF), Fuhrman grade 3 (Figure
2B, C). Immunohistochemically, tumor tissue was cyto-
keratin positive and vimentin negative and hystoche-
mically, coloid iron was negative. According to WHO
2004 classification of renal cell carcinomas4, this tumor is
of clear cell type, and according to TNM classification5, it
corresponds to T1aN0MX.
Gross examination of the resected material from uri-
nary bladder with transuretheral resection method re-
vealed up to ten papillary pieces of tissue up to 2 cm in di-
ameter. Histological finding corresponds to papillary
transitional cell carcinoma with more than ten layers of
well differentiated atypical urothelium cells with only
few mitoses. There was no invasion to subepithelial con-
nective tissue or muscle layer (Figure 2D). According to
TNM classification of bladder carcinomas, this tumor
corresponds to TaN0MX5.
Histological analysis of lymph nodes on hematoxylin
and eosin sections revealed efacement of lymph node
structure with diffuse proliferation of small lymphocytes,
some of them with prolymphocyte features and a few
blasts. Lymphocytes were immunohistochemically CD79a+,
CD20+ (Figure 2A), CD23+, CD5–, CD 43+ and cycline
D1–. Therefore the diagnosis of B-cell Non-Hodgkin small
lymphocytic lymphoma was made (CLL/SLL).
The patient was released from the hospital eight days
after surgical treatment and was advised to take care for
his accidentally diagnosed lymphoma. Trephine biopsy
was performed two months afterwards and showed the
same lymhocytic infiltration concordant with previously
diagnosed CLL/SLL. At the same time his peripheral
blood count showed normal number of lymphocytes. Pa-
tient refused therapy and came back after two years with
generalized lymphadenopathy and lymphocytosis. There
were 93% of lymphocytes in the bone marrow aspirate.
In the meantime he had no sign of recurrence or progres-
sion in the urinary bladder and in the left kidney. His
general condition rapidly deterriorated and he soon died
after refusing therapy.
Discussion
To our knowledge, the present paper is the first one
reporting synchronous renal cell carcinoma, bladder car-
cinoma and Non Hodgkin lymphoma. The only similar
case to our one is the case of synchronous renal adeno-
carcinoma, transitional cell carcinoma of the renal pelvis
and metastatic renal lymphoma6.
As pointed out in the introduction multiple malignan-
cies occuring in a single patient is not a rare event. Renal
cell carcinoma has been reported to be associated with
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Fig. 1. Computed tomography of the abdomen and pelvis: A – tu-
mor in the urinary bladder with contrast applied (arrow), B – the
same tumor without contrast; C – renal tumor without and D –
with contrast applied.
Fig. 2. A – lymphatic tissue CD20 (magnification 400´), B – re-
nal cell tumor HE (magnification 100´), C – renal cell tumor HE
(magnification 400´), D – urinary bladder tumor HE (magnifi-
cation 100´).
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other primary malignancies. According to Rabbani 27.4%
patients with RCC had a second primary malignancy in
his survey; the five most common being prostate, breast,
colon, bladder cancer and NHL7. Most of them were an-
tecedent (44.5%), with almost similar frequency synchro-
nous (39.2%) and the rest were subsequent (16.2%)7. In
the report from Beisland most of them were subsequent
(46.7%), followed by antecedent (34.8%) and synchro-
nous (18.7%) to the RCC1. In the report from Cheson
some other second malignancies are described such as
lung carcinomas, Hodgkin’s disease, multiple myeloma,
some forms of leukemias etc.8.
There are enough reports about coexisting of renal
cell carcinoma and transitional cell carcinoma in the
pyelon, ureters and urinary bladder to try to connect
these two conditions into a relationship6,9–15. The risk of
bladder and renal cancer was observed in all patients and
according to Hisada the risk of developing them was esti-
mated as the ratio of observed to expected number of
cases and was 1.16 in all observed patients (n=16367) in
their study16. Rabbani observed that among patients
with RCC those with papillary renal carcinoma were at
increased risk of developing subsequnt bladder and pros-
tate cancer17. Beisland also found bladder cancer to be
the most frequent subsequent malignancy to RCC and
not only in the early years after the diagnosis of RCC but
also after an interval of more than 10 years1. This long
interval suggests that the incidence is not related only to
surveillance bias but favores a possibility of a common
enviromental or genetic causal agent. Smoking was among
factors for the high rate of subsequent bladder cancer18.
Other carcinogens excreted through the kidneys could
also influence urothel19,20. According to the literature
there is also evidence about the connection among some
chromosomal aneuploidies in bladder cancer and in chro-
mophilic renal cell carcinoma, showing abnormalities of
chromosomes 7 and 17, particularly trisomy and tetra-
somy21.
There are also enough reported cases of coexistent re-
nal cell carcinoma and malignant lymphoma to suggest
the possibility of a causal relationship between these two
conditons1,17,21–9. Most NHL were of B immunopheno-
type with a slight predominance of extranodal lympho-
mas. Previous epidemiological studies revealed an in-
creased incidence of RCC in patients with NHL. The
basis for the association between RCC and antecedent
NHL was attributed mostly to the consequences of the
lymphoma treatment23. In the report from Hisada et al.
the overall risk of developing a second neoplasm is signif-
icantly elevated in persons with CLL compared with
those in the general population16. It seems to be very pos-
sible that myelosuppression and consequent immuno-
logic impairment together with some other factors like
initial treatment, cigarette smoking etc. plays an impor-
tant role in pathogenesis of second cancers in such pa-
tients. On the other hand population based studies failed
to identify an increased risk of renal cancer after NHL.
Rabban in his study showed that only white males and
females had a significantly increased risk of RCC after
NHL and that risk was limited to the first year of fol-
low-up suggesting detection or surveillance bias17. This is
concordant with other reports where the highest inci-
dence of RCC after NHL was within one year of diagno-
sis28. In some studies the same number of synchronous
RCC and NHL as antecedent NHL and RCC was ob-
served while NHL was rare as subsequent case to RCC17.
Synchronous RCC and NHL as well as subsequent NHL
could not be treatement related and no definite etiology,
including genetic basis, has been reported linking these
tumors7,23.
The etiology of multiple primary malignant tumors is
complex and includes, as previously mentioned, envi-
romental factors, genetic predisposition, immunologic
impairment, previous medical treatment, gender and
hormonal factors1. The problem is the impact on overall
survival by synchronous cancers, which was the case in
our patient as well. However, he died sooner because of
refusing treatment and neglecting his lymphoma. The
treatment of patients with multiple primary tumors
should be based on evaluation of the status of each malig-
nant disease. Additional problem is, of course, the mean
age of these patients, which is higher than in patients
with one neoplasm3 and thus making the prognosis even
worse30.
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KARCINOM BUBRE@NIH STANICA S ISTOVREMENIM KARCINOMOM PRIJELAZNOG EPITELA
MOKRA]NOG MJEHURA I NON-HODGKIN LIMFOMOM
S A @ E T A K
Prikazujemo slu~aj 71-godi{njeg bolesnika s vi{estrukim primarnimmalignomima, koji uklju~uju karcinom bubrega
i mokra}nog mjehura, zajedno s limfomom. Bolesnik je primljen na lije~enje zbog bezbolne hematurije. Pretrage su
prikazale tumor desnog bubrega i papilarni tumor u mokra}nom mjehuru, kao i pove}ane paraaortalne i parakavalne
limfne ~vorove. U smislu lije~enja su u~injeni trasuretralna resekcija tumora mokra}nog mjehura (TUR), radikalna
nefrektomija desnog bubrega i retroperitonealna limfadenektomija. Nakon patohistolo{kog pregleda, zajedno s imuno-
histokemijskim pretragama, postavljena je kona~na dijagnoza karcinoma bubre`nih stanica, karcinoma prijelaznog epi-
tela mokra}nog mjehura te B-sitnostani~nog Non-Hodgkin limfoma.
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